Phaseline

Targets › CCR9

CCR9 (C-C chemokine receptor type 9): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Receptor for chemokine SCYA25/TECK. Subsequently transduces a signal by increasing the intracellular calcium ions level..; FUNCTION: (Microbial infection) Alternative coreceptor with CD4 for HIV-1 infection. (UniProt, P51686)

Open in Phaseline: the race on CCR9, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The First Affiliated Hospital of Soochow UniversityCXCR4-enabled CCR9 chimeric antigen receptor T-cell injection
CAR-T cells engineered to express chimeric antigen receptors targeting CXCR4 and CCR9
CXCR4, CCR9Phase 1Relapsed/Refractory T-lymphoblastic Leukemia/LymphomaDec 2026
University College, LondonCARCCR9 T cells
anti-CCR9 CAR T cell therapy
CCR9Phase 1T Cell Acute Lymphoblastic LeukemiaDec 2027

Conditions

T Cell Acute Lymphoblastic Leukemia (1) Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma (1)

Modalities

other (2)

Companies

University College, London (1) The First Affiliated Hospital of Soochow University (1)

Related targets

CXCR4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.